InsiderTrades.com logo
The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way
From Smallcaps Daily   |   Ad
See how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.
Click to read

PLT Insider Trading

Insider Ownership Percentage: 48.18%
Insider Buying (Last 12 Months): A$266,259.26
Insider Selling (Last 12 Months): A$0.00

Plenti Group Insider Trading History Chart

This chart shows the insider buying and selling history at Plenti Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Plenti Group Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 02/22/2021 10:05 AM ET

This chart shows the closing price history over time for PLT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Fidelity, Bezos, Goldman Bet Big on Tiny Biotech
From Behind the Markets   |   Ad
Are you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.
Don't miss out on the "next Ozempic" >>>

Plenti Group Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2024Daniel FoggoInsiderBuy183,935A$0.71A$129,674.18
12/8/2023Daniel FoggoInsiderExercise280,771A$0.68A$190,924.28
12/4/2023Daniel FoggoInsiderBuy12,000A$2.27A$27,228.00
12/1/2023Daniel FoggoInsiderBuy20,000A$0.63A$12,660.00
9/1/2023Daniel FoggoInsiderIssued1,568,801A$0.35A$541,236.35
7/10/2023Daniel FoggoInsiderBuy254,466A$0.38A$96,697.08
6/2/2023Daniel FoggoInsiderExpiry10,542A$0.43A$4,533.06
3/13/2023Peter BehrensInsiderSell1,337,124A$0.42A$561,592.08
12/19/2022Stephen BentonInsiderBuy500,000A$1.00A$500,000.00
11/17/2022Daniel FoggoInsiderBuy64,000A$0.47A$29,824.00
8/18/2022Daniel FoggoInsiderIssued826,403A$0.77A$636,330.31
7/11/2022Daniel FoggoInsiderExpiry10,544A$0.68A$7,169.92
6/10/2022Daniel FoggoInsiderBuy11,475A$0.74A$8,491.50
6/8/2022Daniel FoggoInsiderBuy76,433A$0.71A$54,038.13
6/3/2022Daniel FoggoInsiderBuy30,000A$0.75A$22,440.00
6/1/2022Martin DalgleishInsiderExpiry150,000A$0.75A$112,500.00
2/4/2022Daniel FoggoInsiderBuy34,999A$1.17A$41,018.83
2/2/2022Daniel FoggoInsiderBuy18,000A$1.21A$21,798.00
5/31/2021Mary PloughmanInsiderBuy20,000A$1.20A$24,020.00
See Full Table
Incredible Opportunity to Retire FAST!
From Crypto 101 Media   |   Ad
A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.
Click here to get instant access to the guide

SEC Filings (Institutional Ownership Changes) for Plenti Group (ASX:PLT)

15.03% of Plenti Group stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Plenti Group Limited engages in the fintech lending business in Australia. The company offers personal, car, wedding, legal fee, motorcycle, and dental loans; green, holiday, debt consolidation, and EV loans, as well as engages in auto refinancing activities. It also offers automotive and renewable energy related loans. Plenti Group Limited was founded in 2014 and is headquartered in Sydney, Australia.
Read More on Plenti Group

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Who are the company insiders with the largest holdings of Plenti Group?

Plenti Group's top insider shareholders include:
  1. Daniel Foggo (Insider)
  2. Martin Dalgleish (Insider)
  3. Peter Behrens (Insider)
  4. Stephen Benton (Insider)
Learn More about top insider investors at Plenti Group.
The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way
From Smallcaps Daily   |   Ad
See how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.
Click to read